Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Centre, Retrospective Study Assessing the Efficacy and Safety of Tocilizumab(TCZ) for the Treatment of Severe and/or Refractory Behcet's Disease (BD)

Trial Profile

A Single-Centre, Retrospective Study Assessing the Efficacy and Safety of Tocilizumab(TCZ) for the Treatment of Severe and/or Refractory Behcet's Disease (BD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Behcet's syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Jun 2018 Results (n=7) presented at the 19th Annual Congress of the European League Against Rheumatism
    • 13 Dec 2017 New trial record
    • 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top